Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients with Pseudomonas Aeruginosa (Pa)
Phase 1
Recruiting
- Conditions
- Non-Cystic Fibrosis Bronchiectasis
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Thirty Respiratory Limited
- Target Recruit Count
- 60
- Registration Number
- NCT06663176
- Locations
- πΊπ¦
ARENSIA Exploratory Medicine, Kyiv, Ukraine
Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis
Phase 2
Active, not recruiting
- Conditions
- Rifampicin Susceptible Pulmonary Tuberculosis
- Interventions
- Drug: HRZE
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Thirty Respiratory Limited
- Target Recruit Count
- 75
- Registration Number
- NCT06041919
- Locations
- πΏπ¦
TASK Clinical Research Centre, Cape Town, Bellville, South Africa
COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Thirty Respiratory Limited
- Target Recruit Count
- 88
- Registration Number
- NCT04858451
- Locations
- π¬π§
Medicines Evaluation Unit, Manchester, United Kingdom
π¬π§The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)
Phase 2
Withdrawn
- Conditions
- Respiratory Viral InfectionRespiratory Tract DiseasesCOVID-19 Respiratory Infection
- Interventions
- Drug: RESP301 (a nitric oxide generating solution)Drug: Standard of Care (SOC)
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Thirty Respiratory Limited
- Registration Number
- NCT04842331
- Locations
- π¬π§
Imperial College Healthcare NHS Trust, London, United Kingdom
A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19
Phase 2
Completed
- Conditions
- COVID-19
- Interventions
- Other: Standard of CareDrug: RESP301, a Nitric Oxide generating solution
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Thirty Respiratory Limited
- Target Recruit Count
- 19
- Registration Number
- NCT04460183
- Locations
- π¬π§
Imperial College Healthcare NHS Trust, St. Mary's Hospital, London, United Kingdom
π¬π§Royal Preston Hospital, Preston, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath